

Table 19.30
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2009-2015

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	103,504	70.7 (70.4 , 71.1)	90.3 (89.3 , 91.1)	76.7 (76.3 , 77.2)	61.4 (60.7 , 62.1)				
1 Hodgkin Lymphoma	8,077	85.6 (84.6 , 86.5)	97.3 (95.7 , 98.3)	88.4 (87.4 , 89.4)	58.4 (54.2 , 62.3)				
2 Non-Hodgkin lymphoma	93,329	69.8 (69.4 , 70.3)	88.7 (87.5 , 89.7)	75.4 (74.9 , 75.9)	62.0 (61.3 , 62.7)				
2(a) Non-Hodgkin lymphoma, B-cell	86,191	70.3 (69.8 , 70.7)	89.5 (88.3 , 90.6)	76.3 (75.8 , 76.9)	62.5 (61.8 , 63.3)				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	4,673	68.3 (66.7 , 69.8)	88.3 (86.8 , 89.6)	42.0 (38.9 , 45.0)	14.0 (9.3 , 19.7)				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	76,969	70.6 (70.1 , 71.0)	93.8 (91.7 , 95.4)	77.7 (77.2 , 78.3)	63.1 (62.3 , 63.8)				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	20,318	80.4 (79.5 , 81.3)	89.0 (43.1 , 98.4)	87.7 (86.6 , 88.6)	74.7 (73.2 , 76.1)				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	17,359	83.9 (82.9 , 84.9)	85.8 (33.2 , 97.9)	91.0 (89.9 , 91.9)	78.4 (76.8 , 79.9)				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	59	59.5 (42.0 , 73.3)	- (- , -)	68.8 (41.3 , 85.3)	49.0 (26.6 , 68.1)				
2(a) 2.1.3. Mantle-cell lymphoma	2,900	59.8 (57.3 , 62.3)	- (- , -)	69.4 (66.1 , 72.5)	51.5 (47.7 , 55.2)				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,783	80.8 (77.3 , 83.8)	- (- , -)	88.4 (84.1 , 91.6)	76.2 (71.0 , 80.5)				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	753	80.5 (75.0 , 85.0)	- (- , -)	84.9 (77.8 , 89.9)	78.0 (70.0 , 84.1)				
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,030	81.1 (76.3 , 85.0)	- (- , -)	90.9 (84.9 , 94.6)	74.9 (67.8 , 80.6)				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	19,607	63.3 (62.4 , 64.1)	92.9 (89.0 , 95.5)	70.6 (69.6 , 71.7)	54.2 (52.8 , 55.7)				
2(a) 2.3.1. DLBCL, NOS ^c	19,365	63.1 (62.2 , 64.0)	93.2 (89.2 , 95.8)	70.5 (69.4 , 71.5)	54.3 (52.8 , 55.7)				
2(a) 2.3.2. Intravascular large B-cell lymphoma	27	31.5 (14.0 , 50.7)	- (- , -)	47.3 (21.4 , 69.5)	10.6 (0.6 , 37.9)				
2(a) 2.3.3. Primary effusion lymphoma	42	54.2 (36.4 , 68.9)	- (- , -)	49.0 (30.4 , 65.2)	70.5 (22.4 , 92.1)				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	173	88.8 (82.3 , 93.1)	88.8 (61.7 , 97.1)	91.1 (84.1 , 95.1)	56.5 (22.4 , 80.5)				
2(a) 2.4. Burkitt lymphoma/leukemia	1,587	65.3 (62.6 , 67.9)	93.1 (89.7 , 95.4)	59.8 (56.2 , 63.1)	40.0 (32.1 , 47.7)				
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,689	88.7 (86.9 , 90.3)	100.0 (- , -)	92.9 (91.1 , 94.3)	84.0 (80.6 , 86.8)				
2(a) 2.5.1. Splenic MZL	404	84.4 (77.4 , 89.3)	- (- , -)	86.8 (78.9 , 91.9)	81.6 (69.1 , 89.4)				
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,853	93.3 (91.0 , 95.0)	100.0 (- , -)	95.4 (93.2 , 96.9)	90.5 (85.8 , 93.7)				
2(a) 2.5.3. Nodal MZL	1,432	80.7 (77.2 , 83.8)	100.0 (- , -)	88.2 (84.5 , 91.1)	72.7 (66.7 , 77.8)				
2(a) 2.6. Follicular lymphoma	8,820	88.4 (87.2 , 89.5)	96.9 (78.6 , 99.6)	91.8 (90.7 , 92.8)	83.3 (81.0 , 85.4)				
2(a) 2.7. Hairy-cell leukemia	1,255	94.7 (91.8 , 96.6)	- (- , -)	96.6 (95.1 , 97.7)	87.8 (79.5 , 92.9)				
2(a) 2.8. Plasma cell neoplasms	18,900	52.1 (51.0 , 53.1)	100.0 (- , -)	61.9 (60.5 , 63.3)	43.9 (42.5 , 45.4)				
2(a) 2.8.1. Plasmacytoma	1,214	69.4 (65.6 , 72.9)	100.0 (- , -)	77.5 (73.1 , 81.2)	57.6 (50.6 , 64.0)				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	17,686	50.8 (49.8 , 51.9)	100.0 (- , -)	60.4 (59.0 , 61.9)	43.3 (41.8 , 44.7)				
2(a) 2.9. Heavy chain disease	10	59.4 (18.0 , 85.4)	100.0 (- , -)	84.2 (11.0 , 98.7)	0.0 (- , -)				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	4,549	67.7 (65.6 , 69.6)	92.0 (73.6 , 97.8)	75.6 (73.1 , 78.0)	61.2 (58.1 , 64.2)				

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2009-2015

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	6,775	65.2 (63.8 , 66.6)	85.7 (82.9 , 88.2)	67.1 (65.3 , 68.8)	52.8 (49.7 , 55.8)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	131	63.8 (54.6 , 71.7)	91.7 (81.1 , 96.5)	43.0 (29.4 , 55.9)	0.0 (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	6,635	65.3 (63.8 , 66.7)	85.1 (82.0 , 87.7)	67.6 (65.8 , 69.3)	53.0 (49.9 , 56.1)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,633	89.5 (86.6 , 91.8)	100.0 (- , -)	90.9 (88.0 , 93.2)	85.6 (78.1 , 90.6)			
2(b) 2.1.1. Mycosis fungoides	1,575	90.9 (88.0 , 93.1)	100.0 (- , -)	91.7 (88.8 , 93.9)	88.1 (80.2 , 93.0)			
2(b) 2.1.2. Sezary syndrome	58	48.9 (29.1 , 66.0)	- (- , -)	52.0 (23.3 , 74.5)	47.8 (22.5 , 69.3)			
2(b) 2.2. Peripheral T-cell lymphoma	3,446	57.0 (55.0 , 59.0)	85.7 (78.6 , 90.6)	63.3 (60.8 , 65.7)	44.2 (40.5 , 47.9)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,268	40.3 (37.1 , 43.5)	69.0 (47.3 , 83.2)	48.8 (44.6 , 52.8)	27.2 (22.4 , 32.2)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	437	36.3 (30.7 , 41.8)	100.0 (- , -)	40.9 (32.9 , 48.8)	31.8 (24.1 , 39.8)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	34	87.6 (63.3 , 96.2)	75.2 (12.6 , 96.2)	89.6 (64.0 , 97.3)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	680	64.2 (59.8 , 68.3)	88.6 (79.8 , 93.7)	67.7 (62.4 , 72.4)	42.7 (33.1 , 51.9)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	45	39.9 (24.0 , 55.3)	66.8 (5.3 , 94.6)	39.7 (21.9 , 56.9)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	38	9.7 (2.1 , 24.6)	- (- , -)	16.7 (4.2 , 36.5)	0.0 (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	671	84.7 (79.8 , 88.4)	100.0 (- , -)	88.0 (83.1 , 91.6)	77.7 (66.7 , 85.4)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	273	86.7 (78.7 , 91.8)	90.9 (50.8 , 98.7)	90.3 (81.9 , 94.9)	80.4 (62.3 , 90.4)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,146	66.2 (62.9 , 69.2)	83.9 (80.1 , 87.1)	50.4 (44.9 , 55.6)	19.4 (9.7 , 31.5)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	284	42.3 (35.3 , 49.2)	63.7 (29.7 , 84.5)	41.5 (33.3 , 49.5)	39.7 (25.5 , 53.4)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	12	59.5 (23.4 , 83.1)	- (- , -)	68.3 (18.6 , 91.8)	46.1 (4.5 , 82.4)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	114	17.8 (9.8 , 27.8)	- (- , -)	23.9 (12.3 , 37.5)	8.9 (1.7 , 23.6)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	9	31.4 (4.0 , 66.0)	- (- , -)	27.1 (1.0 , 69.3)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	363	50.0 (44.1 , 55.7)	81.1 (66.6 , 89.7)	51.3 (43.2 , 58.7)	35.6 (25.2 , 46.0)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	125	53.3 (43.7 , 62.0)	82.4 (67.6 , 90.8)	50.0 (32.4 , 65.2)	20.4 (8.8 , 35.4)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	10	49.6 (12.6 , 78.8)	- (- , -)	- (- , -)	38.3 (4.4 , 74.5)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	228	47.9 (40.0 , 55.3)	50.0 (0.6 , 91.0)	50.7 (41.6 , 59.2)	41.9 (27.8 , 55.3)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,929	67.8 (66.3 , 69.3)	88.3 (86.8 , 89.6)	42.3 (39.3 , 45.2)	14.8 (10.3 , 20.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	163	80.6 (72.8 , 86.3)	- (- , -)	83.5 (74.2 , 89.6)	73.2 (57.0 , 84.1)			
4 Lymphoid neoplasm, NOS ^c	1,935	49.3 (46.4 , 52.1)	83.6 (72.1 , 90.7)	60.0 (56.0 , 63.8)	38.6 (34.5 , 42.6)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.